drugset
drugset / Trial / NCT04600284

Evaluating the Pharmacokinetic Interaction Between AD-2101 and AD-2102

NCT04600284 ↗

Phase 1 Completed 25 enrolled Addpharma Inc.
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to evaluate the Pharmacokinetic Interaction Between AD-2101 and AD-2102 in healthy male subjects.

Timeline

Start
2020-11-16
Primary completion
2021-01-20
Completion
2021-04-30

Drugs

EvaluationDrugModalityDoseRoute
Subject AD-2101 Unknown — —
Subject AD-2102 Unknown 25 mg —

Indications

hypertensive disorder